The two available pneumonia vaccines recommended for older adults are equally good at safeguarding the health of people with chronic obstructive pulmonary disease. But Prevnar13 appears to offer longer-term protection, investigators say.
CMS issues reprieve for 2,500 nursing homes yet to report COVID vaccination rates … Former CMS administrator says nursing homes will remain key test sites for COVID therapies, other treatments … Philips recalls CPAP machines over cancer concerns … Gene treatment could slow Alzheimer’s without targeting brain plaques, new study shows … Jury trial set for maker of Alzheimer’s drug Namenda; company allegedly kept generic off the market
Approximately 40% of Medicare beneficiaries with chronic obstructive pulmonary disease have limited access to pulmonary rehabilitation services due to their distance from rehab centers. That’s according to research presented at the American Thoracic Society’s 2021 International Conference.
The biologic drug hyaluronan improved lung function in patients hospitalized for severe exacerbation of chronic obstructive pulmonary disease, a new study finds.
Starting pulmonary rehab within 90 days of hospitalization for COPD has significant survival benefits. More sessions further improve patient outcomes.
Among coronavirus symptoms, breathing difficulties are significantly tied to severe illness progression and ICU admission, say investigators.
Three-drug combination reduces all-cause COPD mortality by 42% … COVID-19 death rate lower than estimated, at 1.4% in outbreak epicenter … FDA: Stop SLGT2 inhibitors for diabetes prior to surgery
Leading medical institutions are proposing new diagnostic criteria for chronic obstructive pulmonary disease, the nation’s fourth leading cause of death.
People who go to a skilled nursing facility after being hospitalized for chronic obstructive pulmonary disease are about twice as likely to die within a year, according to recently released findings.
The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.
